
Supplements and Featured Publications
- Navigating Optimal Dosing and Modifications in CML Management
- Volume 1
- Issue 1
Response-Based Dosing and Mutation Testing Guide Ponatinib Use in CML
Five-year data from the randomized phase 2 OPTIC trial (NCT02467270) showed that response-based ponatinib (Iclusig) dosing sustained molecular responses and survival in patients with resistant chronic-phase chronic myeloid leukemia (CML).1 Patients with BCR::ABL1 T315I mutations derived the greatest benefit from the highest starting dose, and pairing this strategy with well-timed mutation testing can help clinicians individualize treatment, according to Jorge Cortes, MD.
“This was the first study [of ponatinib] that prospectively investigated lowering the dose because of response, not because of toxicity,” Cortes said in an exclusive interview with OncLive®.
In OPTIC, patients (n = 283) whose disease had become resistant to or intolerant of 2 or more prior TKIs, or who had a BCR::ABL1 T315I mutation, were randomly assigned to ponatinib starting doses of 45 mg (n = 94), 30 mg (n = 95), or 15 mg (n = 94) once daily. Those in the 45- and 30-mg cohorts stepped down to 15 mg once BCR::ABL1 transcript levels reached 1% or less on the International Scale. In the primary analysis, 44.1%, 29.0%, and 23.1% of patients in the 45-, 30-, and 15-mg cohorts, respectively, achieved this response at 12 months.2
With a median follow-up of 75 to 78 months, 60%, 41%, and 40% of patients in the respective cohorts reached that threshold by 5 years, and overall survival topped 80% in each cohort.1 Among patients with BCR::ABL1 T315I mutations, 5-year response rates were 64%, 25%, and 16%, and 5-year progression-free survival rates were 58%, 25%, and 31%, respectively. Exposure-adjusted rates of adjudicated arterial occlusive events were 4.1, 3.8, and 2.0 per 100 patient-years in the 45-, 30-, and 15-mg cohorts, respectively.
In the interview, Cortes discussed how OPTIC data help inform his dosing decisions, why he confirms a response before lowering ponatinib intensity, how mutation testing can guide therapy when resistance develops, and the importance of managing comorbidities when selecting a TKI.
Cortes is chief of hematology in the Division of Hematology and Oncology and deputy director of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.
OncLive: How have OPTIC data challenged assumptions about ponatinib starting doses in resistant CML?
Cortes: Before we had this study, we very frequently used lower doses to start with [and] assumed that it was going to work well and decrease the risk [of AEs]. However, we did that more out of personal experience and belief, not with solid data.
OPTIC has helped us quantify the added risk [and] the added benefit, and put it in perspective in different scenarios, [such as] for patients with mutations [or] no mutations, so that we can decide when it is appropriate to use ponatinib and what is the right way to do it to optimize that risk:benefit ratio.
What should clinicians understand regarding ponatinib dose reductions after a response in CML?
[OPTIC] was the first study that prospectively investigated lowering the dose [of ponatinib] because of response, not because of toxicity. We also adjust the dose for toxicity, but [in OPTIC], it was intentional. Once the patient responded, [we] lowered the dose.
We had always been using TKIs at the established dose and kept that dose. [OPTIC data] show that the approach of lowering the dose once a patient responds should be explored more, even with other drugs and other scenarios, so that we can probably maintain patients with a minimally effective dose once they have a good response.
The way OPTIC was designed, once the patient responded, we lowered the dose. In my opinion, it is a little safer in terms of not losing the response [and] to confirm that the patient has achieved a response. What I am doing now is not [lowering the dose] the first time I see the response. We recheck, make sure that the response is established and confirmed, and then lower the dose. That is particularly important for patients with BCR::ABL1 T315I [mutations] because they are much more sensitive to the dose.
How do you approach mutation testing when patients with CML develop treatment resistance?
We continue to learn about mutations [and their role in CML]. I never test for mutations at diagnosis, [at least] not for BCR::ABL1 kinase domain mutations because they really do not happen [at that point].
However, once a patient develops resistance, it is important to check for mutations, particularly if we are going to consider changing the drug. First, it can guide which options may be more appropriate for that particular patient. Second, mutations may establish the prognosis and perhaps even guide the dose. We have learned with OPTIC and ponatinib, but also with other drugs, that some mutations may require a higher dose than others. It is important to understand those differences to guide the dose and the drug.
It is also important to recognize that in OPTIC, in patients who do not have mutations— [representing] approximately half of patients [with CML]—those patients actually had the lowest response rate. Evidently, there are other mechanisms of resistance that we have not understood that well.
One [possibility] is mutations in other genes, such as ASXL1. We are starting to do next-generation sequencing [NGS] in those patients because there may be alternative pathways contributing to resistance.
What barriers remain to mutation testing in CML, and when should community oncologists consider broader sequencing?
Fortunately, mutation analysis, both for BCR::ABL1 kinase domain mutations and other genes, is more broadly available and more reliable in academic and commercial laboratories. We have broken that barrier. Before, it was a niche test; now it is more available.
The important thing is understanding when it is appropriate to do this testing. You usually are not going to find [a mutation] in a patient who is not getting to a deep molecular response but is responding well. To me, the optimal setting to look for a mutation is when a patient meets the criteria for resistance or [treatment] failure according to the National Comprehensive Cancer Network [NCCN] or European LeukemiaNet [ELN] classifications. They are very similar. That is when you are more likely to find mutations, and even then, probably only in approximately half of patients. You should check for kinase domain mutations any time the patient meets those criteria.
We are recommending NGS at diagnosis for every patient. We are doing it more as a research tool, but it does not really change the initial treatment. Once a patient has had resistance to 1, and definitely 2, TKIs, it is important [to test] because it could change your approach. For example, in a younger patient who has gone through 2 TKIs and has 1 of these mutations, I would consider transplant higher up in my priorities. That is a setting where it might be appropriate to consider NGS testing to see whether [another mutation] may be part of the reason for resistance.
What practical messages from OPTIC should guide ponatinib use and cardiovascular risk management in CML?
One of the most important values of OPTIC is that ponatinib is a very good drug, but there is a risk of arterial occlusive events. These data show us how to administer ponatinib in a safer way so that we do not deny this option to a patient when it is appropriate. It is not appropriate for every patient, but when it is appropriate, we can use it in the safest possible way, give patients the benefits, and minimize the risk.
We always have to remember to manage comorbidities because these events usually happen in patients who have other comorbidities. We also need to remember that arterial occlusive events happen with all TKIs, probably except imatinib [Gleevec]. The risks differ; ponatinib probably has a higher risk than others, but they happen with nilotinib [Tasigna] and dasatinib [Sprycel]. It is important to manage comorbidities and use the appropriate drug at the appropriate dose at the appropriate time.
Editor’s Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.
References
- Kantarjian H, Deininger M, Apperley JF, et al. Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. Leukemia. 2026;40(9):1882-1892. doi:10.1038/s41375-026-03009-x
- Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138(21):2042-2050. doi:10.1182/blood.2021012082
Related to this article








